Advanced Melanoma Clinical Trials in New York, New York

4 studies are recruiting for advanced melanoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

    The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity o…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT07504796 on ClinicalTrials.gov

  2. A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

    The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    12 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06594991 on ClinicalTrials.gov

  3. Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

    The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care [SoC], best supp…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    82 in total
    Run by
    Immunocore Ltd

    See if you can join NCT05549297 on ClinicalTrials.gov

  4. IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

    This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Columbia University Medical Center, New York, New York
    Locations
    211 in total
    Run by
    Immunocore Ltd

    See if you can join NCT06112314 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.